Sharon Benzeno Sells 11,034 Shares of Adaptive Biotechnologies (NASDAQ:ADPT) Stock

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) insider Sharon Benzeno sold 11,034 shares of the business’s stock in a transaction dated Friday, June 26th. The stock was sold at an average price of $21.00, for a total value of $231,714.00. Following the transaction, the insider owned 272,751 shares in the company, valued at approximately $5,727,771. This represents a 3.89% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Sharon Benzeno also recently made the following trade(s):

• On Monday, June 29th, Sharon Benzeno sold 154,768 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $21.14, for a total value of $3,271,795.52.

Adaptive Biotechnologies Stock Performance

ADPT stock opened at $22.37 on Thursday. The firm has a market cap of $3.58 billion, a P/E ratio of -67.79 and a beta of 2.07. Adaptive Biotechnologies Corporation has a 1 year low of $9.96 and a 1 year high of $22.54. The stock has a 50-day simple moving average of $15.81 and a 200-day simple moving average of $15.79.

Adaptive Biotechnologies (NASDAQ:ADPT) last released its quarterly earnings results on Tuesday, May 5th. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.16) by $0.03. The firm had revenue of $70.87 million for the quarter, compared to analyst estimates of $61.03 million. Adaptive Biotechnologies had a negative return on equity of 40.06% and a negative net margin of 16.82%.Adaptive Biotechnologies’s revenue for the quarter was up 35.1% on a year-over-year basis. During the same period in the previous year, the company posted ($0.20) EPS. On average, equities research analysts predict that Adaptive Biotechnologies Corporation will post -0.47 EPS for the current year.

Wall Street Analysts Forecast Growth

ADPT has been the subject of a number of recent analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Adaptive Biotechnologies in a report on Monday, April 20th. Guggenheim boosted their price objective on shares of Adaptive Biotechnologies from $21.00 to $22.00 and gave the stock a “buy” rating in a report on Monday. BTIG Research restated a “buy” rating and set a $22.00 target price on shares of Adaptive Biotechnologies in a research note on Wednesday, June 17th. Wall Street Zen lowered Adaptive Biotechnologies from a “buy” rating to a “hold” rating in a research report on Saturday, March 7th. Finally, Morgan Stanley cut their price target on Adaptive Biotechnologies from $21.00 to $18.00 and set an “equal weight” rating on the stock in a research note on Tuesday, May 12th. Five investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $20.50.

Institutional Trading of Adaptive Biotechnologies

Several institutional investors have recently added to or reduced their stakes in the stock. Caitong International Asset Management Co. Ltd bought a new position in Adaptive Biotechnologies during the 4th quarter valued at $28,000. EverSource Wealth Advisors LLC raised its stake in shares of Adaptive Biotechnologies by 197.1% in the 4th quarter. EverSource Wealth Advisors LLC now owns 2,359 shares of the company’s stock valued at $38,000 after purchasing an additional 1,565 shares in the last quarter. KBC Group NV acquired a new stake in shares of Adaptive Biotechnologies in the 1st quarter valued at about $45,000. Assetmark Inc. lifted its position in shares of Adaptive Biotechnologies by 867.9% during the fourth quarter. Assetmark Inc. now owns 3,020 shares of the company’s stock worth $49,000 after purchasing an additional 2,708 shares during the last quarter. Finally, T. Rowe Price Investment Management Inc. bought a new position in shares of Adaptive Biotechnologies during the fourth quarter worth about $51,000. 99.17% of the stock is owned by institutional investors and hedge funds.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.